Impact BioMedical, Inc. - Asset Resilience Ratio
Impact BioMedical, Inc. (IBO) has an Asset Resilience Ratio of 0.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IBO working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Impact BioMedical, Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Impact BioMedical, Inc. (IBO) total assets.
Liquid Assets Composition Over Time
This chart breaks down Impact BioMedical, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore IBO long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $12.00K | 0.07% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $12.00K | 0.07% |
Asset Resilience Insights
- Limited Liquidity: Impact BioMedical, Inc. maintains only 0.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Impact BioMedical, Inc. Industry Peers by Asset Resilience Ratio
Compare Impact BioMedical, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Impact BioMedical, Inc. (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Impact BioMedical, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 19.69% | $4.00 Million | $20.29 Million | +19.69pp |
| 2023-12-31 | 0.00% | $1.00K | $44.63 Million | 0.00pp |
| 2022-12-31 | 0.00% | $2.00K | $46.50 Million | -- |
About Impact BioMedical, Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application … Read more